Last updated: February 15, 2026
Clinical Trials Update for ANUSOL HC
ANUSOL HC (hydrocortisone 1%), with or without other ingredients, is a topical corticosteroid primarily used for hemorrhoids, anal fissures, and other inflammatory anorectal conditions. The drug has a well-established safety profile, with a history of over 30 years of clinical use. Unlike many drugs in development, ANUSOL HC has no recent major clinical trials announced or ongoing. It remains a marketed product, with formulations available over the counter or via prescription depending on regional regulations.
Regulatory Status:
Based on public databases, ANUSOL HC has not undergone recent clinical trial registration or phase-specific evaluations in major clinical trial registries such as ClinicalTrials.gov since 2018. The product’s primary approvals have been based on existing safety and efficacy profiles for corticosteroid formulations treating anorectal conditions.
Research Activity:
Limited academic research exploring new indications or formulations. Most recent publications focus on topical corticosteroids' safety, efficacy, and long-term effects rather than novel clinical trials for ANUSOL HC specifically.
Market Analysis for ANUSOL HC
Current Market Position
ANUSOL HC is a branded topical corticosteroid ointment. The drug competes in the niche of hemorrhoid treatments, which includes ointments, suppositories, and alternative therapies.
Market Size and Sales:
Estimates suggest that the global hemorrhoid treatment market was valued at approximately USD 940 million in 2022[1]. ANUSOL HC holds a significant portion within the topical corticosteroid segment, especially in North America and Europe, where corticosteroids are standard for symptomatic relief.
Regional Availability:
- United States: Available OTC in some formulations for external hemorrhoids; prescription required for higher potency or combined formulations.
- Europe: Available under various brand names, including ANUSOL, with formulations including hydrocortisone.
- Asia-Pacific: Market penetration varies; some countries have local or generic corticosteroid products.
Distribution Channels:
OTC pharmacies dominate sales, supported by direct-to-consumer advertising for hemorrhoid symptomatic relief. Physician prescriptions are common when formulations include higher potency or are combined with other active ingredients.
Competitive Landscape
The market features several primary competitors:
| Brand Name |
Active Ingredients |
Formulation |
Price Range (USD) |
Market Share (Estimate) |
| Preparation H |
Phenylephrine, Pramoxine |
Ointments, suppositories |
5–15 per unit |
30% |
| Anusol/Anusol HC |
Hydrocortisone 1% |
Ointments, suppositories |
10–25 per unit |
15-20% |
| Rectogesic |
Glyceryl trinitrate |
Ointments |
20–30 per unit |
10% |
In the corticosteroid segment, ANUSOL HC faces competition from lower-cost generics and other formulations with similar or higher potency hydrocortisone.
Market Trends
- An increasing preference for OTC remedies facilitates market growth.
- Rise in sedentary lifestyles and aging demographics bolster demand for hemorrhoid treatment products.
- Growing awareness of minimally invasive treatments influences the market, but topical treatments like ANUSOL HC remain primary first-line options.
Market Projection
Forecast Period: 2023–2028
CAGR: 4.5%
Assumptions:
- Continued prevalence of hemorrhoids and anorectal inflammatory conditions.
- Stable OTC sales driven by aging population and increased health awareness.
- Moderate innovation, with no significant new clinical trials or formulation improvements announced.
Predictions:
- The global hemorrhoid treatment market will approach USD 1.4 billion by 2028.
- The corticosteroid segment will sustain a 15% share, with ANUSOL HC expected to retain a substantial portion owing to its established presence.
- Emergence of new generic formulations will exert downward pricing pressure, potentially reducing per-unit prices by 10-15%.
Potential Growth Drivers:
- Increased marketing efforts in emerging markets.
- Development of combination products with analgesics or anesthetics.
- Higher acceptance of OTC products through regulatory liberalization.
Risks:
- Regulatory restrictions on corticosteroid use due to side effects, especially with prolonged use.
- Competition from non-steroidal topical agents or advanced minimally invasive procedures.
Summary and Key Takeaways
ANUSOL HC remains a widely used corticosteroid treatment for hemorrhoids and anorectal inflammation, with no significant recent updates in clinical trial activity. The product sustains a mature market segment characterized by OTC availability and regional variation in formulary status. Market growth continues at a moderate rate driven by demographic shifts and consumer trends toward OTC therapies. Competition from generic alternatives and the potential for regulatory changes regarding corticosteroid safety are key factors to monitor.
FAQs
1. Are there ongoing clinical trials evaluating new formulations or indications for ANUSOL HC?
No current clinical trials for ANUSOL HC are registered or publicly announced as of 2023.
2. What is the main competitive advantage of ANUSOL HC?
Its long-established safety profile and broad regional availability make it a trusted choice in hemorrhoid treatment.
3. How do regulatory restrictions impact the market for ANUSOL HC?
Restrictions on corticosteroid potency and duration of use may limit formularies and OTC accessibility, especially in countries with stringent drug safety regulations.
4. What are the primary drivers for market growth in the hemorrhoid treatment segment?
Demographic aging, increased health awareness, and OTC product accessibility sustain growth.
5. What risks could impact future sales?
Regulatory clampdowns on corticosteroids, aggressive generic competition, and shifts toward alternative minimally invasive treatments could reduce market share.
References
- MarketResearch.com. “Global Hemorrhoid Treatment Market Size & Share Report 2022-2028.”
